Skip to content

Evenamide for schizophrenia treatment resistance

Schizophrenia

This 52-week clinical study is sponsored by Newron Pharmaceuticals. The study aims to see how a drug called Evenamide works in people with schizophrenia whose symptoms have not improved enough with their current medication. Evenamide will be tested as an extra treatment added to the antipsychotic medicine you are already taking. The goal of this study is to find out if Evenamide is safe and if it can help improve symptoms when used together with standard antipsychotic drugs.

null

Participation Requirements

  • Sex:

    Male, Female

  • Eligible Ages:

    18 to 80

Participation Criteria

Inclusion Criteria:
Ages: 18 years, or older
Diagnosed with Schizophrenia with confirmation of treatment resistance.
Exclusion Criteria:
Diagnosis of schizophreniform disorder
Diagnosis of schizoaffective disorder
Or other primary psychiatric diagnosis, such as bipolar disorder or major depressive
disorder
History or current diagnosis of ‘Substance Use Disorder’ e.g. currently abusing drugs or alcohol or has done so in the past year.
Has known suicidal risk.
Has insulin-dependent diabetes mellitus.

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: REB25-1040